Annual Secretarial Compliance Report for the Financial Year ended March 31, 2025.
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India has filed its Annual Secretarial Compliance Report for FY 2024-25, as required under SEBI's Listing Regulations. The report was issued by practicing company secretary K.G. Saraf of Saraf & Associates on May 9, 2025 and submitted to BSE on May 26, 2025. The review confirms that the company has complied with all applicable SEBI regulations, circulars, and guidelines during the year, with no deviations, violations, or penalties reported. No action was taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries. The company has no material subsidiaries, and several regulations (buyback, ESOP, NCS, delisting) were noted as not applicable during the review period.
This is a routine annual compliance filing with a clean report — no regulatory issues or penalties were flagged, so there is no material impact on shareholders or the stock price.